<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942773</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCPT09_Vori2C19_A</org_study_id>
    <nct_id>NCT00942773</nct_id>
  </id_info>
  <brief_title>Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole</brief_title>
  <official_title>Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

        -  Evaluate the influence of CYP2C19 genotype on PK profiles of voriconazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of voriconazole</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collected by investigator questionnaire and subjects spontaneous report</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CYP2C19 extensive metabolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2C19 heterozygous extensive metabolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2C19 poor metabolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <arm_group_label>CYP2C19 extensive metabolizer</arm_group_label>
    <arm_group_label>CYP2C19 heterozygous extensive metabolizer</arm_group_label>
    <arm_group_label>CYP2C19 poor metabolizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects aged 20 - 50 years.

          2. A body mass index (BMI) in the range 17-28 kg/m2.

          3. Sufficient ability to understand the nature of the study and any hazards of
             participating in it. Provide written informed consent after being fully. informed
             about the study procedures.

        Exclusion Criteria:

          1. Presence or history of severe adverse reaction to any drug or a history of severe
             allergic disease.

          2. Clinically relevant abnormal medical history that could interfere with the objectives
             of the study.

          3. Presence or history of eye disease or eye field defect.

          4. A subject with history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug.

          5. A subject whose liver function test (AST, ALT, GGT, ALP, LDH) result is over 1.25
             times of upper limit of normal range.

          6. A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or
             below 50 mmHg.

          7. Presence or history of drug abuse.

          8. Participation in other clinical trial within 2 months.

          9. Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter
             medication within 1 week before first dose.

         10. Blood donation during 2 months or apheresis during 1 month before the study.

         11. Presence or history of alcohol abuse.

         12. Smoking of more than 10 cigarettes/day.

         13. Use of grapefruit juice, xanthine containing beverage, alcohol or smoking during
             restriction period.

         14. Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>In-Jin Jang</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

